High-Grade Carcinomas Involving the Renal Sinus: Report of a Case and Review of the Differential Diagnosis and Immunohistochemical Expression

Young, Allison M; Kunju, Lakshmi P.

doi:10.5858/arpa.2012-0196-cr

Cited by 12 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of note, in a rare subset of cases, PAX8 positivity has also been documented in upper tract urothelial carcinomas. 1,2 Therefore, this immunophenotype is supportive of a drop metastasis/tumor seeding of the papillary renal cell carcinoma.…”

Section: Path To Patient Image Quizmentioning

confidence: 90%

Papillary Renal Cell Carcinoma With “Drop Metastasis” (Tumor Seeding) Involving the Distal Ureter

Gupta

Erickson

2022

Mayo Clinic Proceedings

View full text Add to dashboard Cite

Section: Path To Patient Image Quizmentioning

confidence: 90%

Papillary Renal Cell Carcinoma With “Drop Metastasis” (Tumor Seeding) Involving the Distal Ureter

Gupta

Erickson

2022

Mayo Clinic Proceedings

View full text Add to dashboard Cite

“…However, the former occurs predominantly in older adults, with a mean age of 55 years, whereas presentation of RMC in patients older than 40 years is extremely uncommon. 20 Additionally, CDC usually displays a tubular or a tubulopapillary pattern, as opposed to the predominantly reticular pattern of RMC. Ohe et al 21 describe a study of 100 cases in which a multinodular infiltrating papillary pattern was statistically significantly more likely to be associated with CDC than with RMC.…”

Section: Collecting Duct Carcinomamentioning

confidence: 99%

Renal Medullary Carcinoma

Elliott

Bruner

2019

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

Renal medullary carcinoma, also referred to as the seventh sickle cell nephropathy, typically affects young African Americans with sickle cell trait, or, less frequently, patients with sickle cell disease. The existence of renal medullary carcinoma without a concomitant hemoglobinopathy is a topic of controversy. The typical patient is a young male of African or Mediterranean descent, with hematuria and/or flank pain. Most patients have metastatic disease at the time of presentation. The tumor is characteristically a poorly circumscribed mass in the medullary region, commonly showing variable amounts of hemorrhage and necrosis. Microscopically, a characteristic reticular or cribriform pattern with a striking desmoplastic stromal response and a robust mixed inflammatory infiltrate is observed. Collecting duct carcinoma, malignant rhabdoid tumor, urothelial carcinoma, and other subtypes of renal cell carcinoma are in the differential diagnosis. Because of the advanced stage of disease at presentation and the aggressive nature of this malignant neoplasm, survival is poor even with chemotherapy; however, isolated reports of prolonged survival have been documented.

show abstract

“…50 Immunohistochemistry may be helpful to distinguish CDC from t-RCC and other high-grade RCC, as CDC typically expresses high-molecular-weight cytokeratin, EMA, and cytokeratin 7 but is negative for CD10, AMACR, and CAIX. 52 The molecular oncogenesis of CDC is not currently well understood, which limits the role for diagnostic molecular testing and/or targeted therapy in these tumors.…”

Section: Hereditary Leiomyomatosismentioning

confidence: 99%

MiT Family Translocation-Associated Renal Cell Carcinoma: A Contemporary Update With Emphasis on Morphologic, Immunophenotypic, and Molecular Mimics

Magers

Udager²,

Mehra³

2015

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

Translocation-associated renal cell carcinoma (t-RCC) is a relatively uncommon subtype of renal cell carcinoma characterized by recurrent gene rearrangements involving the TFE3 or TFEB loci. TFE3 and TFEB are members of the microphthalmia transcription factor (MiT) family, which regulates differentiation in melanocytes and osteoclasts, and MiT family gene fusions activate unique molecular programs that can be detected immunohistochemically. Although the overall clinical behavior of t-RCC is variable, emerging molecular data suggest the possibility of targeted approaches to advanced disease. Thus, distinguishing t-RCC from its morphologic, immunophenotypic, and molecular mimics may have important clinical implications. The differential diagnosis for t-RCC includes a variety of common renal neoplasms, particularly those demonstrating clear cell and papillary features; in addition, because of immunophenotypic overlap and/or shared molecular abnormalities (ie, TFE3 gene rearrangement), a distinctive set of nonepithelial renal tumors may also warrant consideration. Directed ancillary testing is an essential aspect to the workup of t-RCC cases and may include a panel of immunohistochemical stains, such as PAX8, pancytokeratins, epithelial membrane antigen, carbonic anhydrase IX, HMB-45, and Melan-A. Dual-color, break-apart fluorescent in situ hybridization for TFE3 or TFEB gene rearrangement may be helpful in diagnostically challenging cases or when molecular confirmation is needed.

show abstract

High-Grade Carcinomas Involving the Renal Sinus: Report of a Case and Review of the Differential Diagnosis and Immunohistochemical Expression

Cited by 12 publications

References 10 publications

Papillary Renal Cell Carcinoma With “Drop Metastasis” (Tumor Seeding) Involving the Distal Ureter

Papillary Renal Cell Carcinoma With “Drop Metastasis” (Tumor Seeding) Involving the Distal Ureter

Renal Medullary Carcinoma

MiT Family Translocation-Associated Renal Cell Carcinoma: A Contemporary Update With Emphasis on Morphologic, Immunophenotypic, and Molecular Mimics

Contact Info

Product

Resources

About